Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

Zenopa, you have done it again! By 'it' I mean you have supported my application to a great company where so far, I feel like I fit right in.
Natasha, 2013

Bristol-Myers Squibb to present liver disease data at EASL

5 April 2012 00:00 in Pharmaceutical Company Product News

Bristol-Myers Squibb is to showcase new clinical data on its liver disease portfolio at the forthcoming annual meeting of the European Association for the Study of the Liver (EASL).

A total of 20 abstracts from the company's portfolio will be presented at the Barcelona event this month, including data on therapies such as daclatasvir, asunaprevir, Lambda, BMS-791325, brivanib and Baraclude.

Key presentations will include analysis of clinical trial data showing the benefits its direct-acting antivirals and Lambda can offer in the treatment of hepatitis C.

The information highlighted at EASL will help expand understanding of Bristol-Myers Squibb's new therapies and support their continuing clinical development.

Dr Brian Daniels, senior vice-president for global development and medical affairs at Bristol-Myers Squibb's research and development division, said: "Bristol-Myers Squibb is at the forefront of discovering, developing and delivering potential treatments for diseases of the liver where there remains considerable unmet medical need."

Last month, the company announced a new alliance with the Duke Translational Medicine Institute, focusing on the development of new therapies in areas such as idiopathic pulmonary fibrosis.ADNFCR-8000103-ID-801334660-ADNFCR

Other news stories from 05/04/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd